Skip to main content

Table 2 Variables with the highest ranking based on ROC curve AUC and sensitivities at 95% specificity

From: DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment

  AUC 95% CI of AUC
DAS28 w22 0.840 0.791–0.889
28 TJC w22 0.797 0.744–0.850
Physician global VAS w22 0.786 0.736–0.836
Patient pain VAS w22 0.764 0.71–0.814
DAS28 w14 0.750 0.685–0.815
Patient disease activity VAS w22 0.750 0.689–0.802
66TJC w22 0.740 0.689–0.791
28TJC w14 0.721 0.662–0.780
66SJC w22 0.717 0.660–0.774
ESR w22 0.716 0.654–0.779
  Sensitivity (%) at 95% specificity level 95% CI of sensitivity
DAS28 w22 42.5 36.9–48.1
Physician global VAS w22 32.7 28.4–37.0
28SJC w22 29.8 24.7–34.9
Patient pain VAS w22 26.8 22.7–30.9
66SJC w22 24.5 20.6–28.4
ESR w22 24.1 19.7–28.5
66SJC w14 23.0 18.6–27.4
CRP w22 21.3 17.3–25.3
Patient disease activity VAS w22 20.4 16.6-4.2
DAS28 w14 20.3 15.3–25.3
  1. AUC, area under the curve; TJC, tender joint count; SJC, swollen joint count; ESR, erythrocyte sedimentation rate; CI, confidence interval; CRP, C-reactive protein; w, week.